

# Vathany Kulasingam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/292198/publications.pdf>

Version: 2024-02-01

84  
papers

3,534  
citations

201674

27  
h-index

144013

57  
g-index

87  
all docs

87  
docs citations

87  
times ranked

6108  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel. Canadian Journal of Neurological Sciences, 2022, 49, 19-28.	0.5	8
2	Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response. journal of applied laboratory medicine, The, 2022, 7, 57-65.	1.3	18
3	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, 7, 1-2.	1.3	0
4	To skim or splice? Comparing the quantification of M-proteins using two peak-integration protocols across multiple electrophoresis platforms. Clinical Biochemistry, 2022, 102, 44-49.	1.9	1
5	Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection. Clinical Chemistry and Laboratory Medicine, 2022, 60, 771-777.	2.3	11
6	Rapid determination of tacrolimus and sirolimus in whole human blood by direct coupling of solid-phase microextraction to mass spectrometry via microfluidic open interface. Analytica Chimica Acta, 2021, 1144, 53-60.	5.4	33
7	Recurring Critical Results and Their Impact on the Volume of Critical Calls at a Tertiary Care Center. journal of applied laboratory medicine, The, 2021, 6, 962-968.	1.3	0
8	Comparing CMIA to PETINIA and Enzyme Immunoassays for Eight TDM Drugs. journal of applied laboratory medicine, The, 2021, 6, 1080-1083.	1.3	0
9	Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice. Journal of Clinical Investigation, 2021, 131, .	8.2	7
10	Prospective observational study and serosurvey of SARS-CoV-2 infection in asymptomatic healthcare workers at a Canadian tertiary care center. PLoS ONE, 2021, 16, e0247258.	2.5	12
11	Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation. Journal of Clinical Microbiology, 2021, 59, .	3.9	112
12	Interpretation and Clinical Value of Serum Anti-PLA2R-Antibody Testing. journal of applied laboratory medicine, The, 2021, 6, 799-803.	1.3	0
13	Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course. Clinical Biochemistry, 2021, 90, 1-7.	1.9	11
14	Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay. Viruses, 2021, 13, 962.	3.3	17
15	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden. F1000Research, 2021, 10, 509.	1.6	6
16	Metabolomics Studies in Psoriatic Disease: A Review. Metabolites, 2021, 11, 375.	2.9	13
17	Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients. Transplantation, 2021, 105, 2175-2183.	1.0	19
18	Serum metabolic fingerprinting of psoriasis and psoriatic arthritis patients using solid-phase microextraction-liquid chromatography-high-resolution mass spectrometry. Metabolomics, 2021, 17, 59.	3.0	19

#	ARTICLE	IF	CITATIONS
19	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3980-3989.	4.7	120
20	Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100155.	3.8	36
21	Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. <i>New England Journal of Medicine</i> , 2021, 385, 1244-1246.	27.0	456
22	Sample stability of autoantibodies: A tool for laboratory quality initiatives. <i>Clinical Biochemistry</i> , 2021, 96, 43-48.	1.9	3
23	Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2021, 224, 1849-1860.	4.0	16
24	SPME-LC/MS-based serum metabolomic phenotyping for distinguishing ovarian cancer histologic subtypes: a pilot study. <i>Scientific Reports</i> , 2021, 11, 22428.	3.3	8
25	Emerging role of clinical mass spectrometry in pathology. <i>Journal of Clinical Pathology</i> , 2020, 73, 61-69.	2.0	30
26	A Puzzling Case of Hyperviscosity Syndrome. <i>Journal of applied laboratory medicine</i> , The, 2020, 5, 209-213.	1.3	0
27	Evaluation of a coated blade spray-tandem mass spectrometry assay as a new tool for the determination of immunosuppressive drugs in whole blood. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 5067-5076.	3.7	24
28	Extracellular Matrix Injury of Kidney Allografts in Antibody-Mediated Rejection: A Proteomics Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2705-2724.	6.1	29
29	Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology. <i>Clinical Biochemistry</i> , 2020, 86, 1-7.	1.9	17
30	A Case of Rapid Deterioration with Marked Hypergammaglobulinemia. <i>Clinical Chemistry</i> , 2020, 66, 1373-1378.	3.2	0
31	Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays. <i>Clinical Biochemistry</i> , 2020, 86, 56-60.	1.9	2
32	Defining appropriate utilization of AST testing. <i>Clinical Biochemistry</i> , 2020, 79, 75-77.	1.9	9
33	Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2568-2574.	2.5	26
34	Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. <i>F1000Research</i> , 2020, 9, 732.	1.6	2
35	What Is Really in This Weight Loss Supplement?. <i>Journal of applied laboratory medicine</i> , The, 2019, 4, 270-273.	1.3	1
36	A patient with monoclonal gammopathy-related nephrotic syndrome revealed no electrophoretic "nephrotic pattern" or skewed free light chain ratio. <i>Clinical Biochemistry</i> , 2018, 51, 110-111.	1.9	0

#	ARTICLE	IF	CITATIONS
37	Introduction to the Special Collection "Beating Cancer with Early Detection: A Seasoned Idea with New Insights. journal of applied laboratory medicine, The, 2018, 3, 155-158.	1.3	0
38	Circulating Tumor DNA for Early Cancer Detection. journal of applied laboratory medicine, The, 2018, 3, 300-313.	1.3	25
39	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. F1000Research, 2018, 7, 189.	1.6	3
40	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. F1000Research, 2018, 7, 189.	1.6	3
41	Urinary adenosine excretion in type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 313, F184-F191.	2.7	46
42	Towards personalized tumor markers. Npj Precision Oncology, 2017, 1, 17.	5.4	20
43	Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. F1000Research, 2017, 6, 1832.	1.6	13
44	Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. F1000Research, 2017, 6, 1832.	1.6	15
45	The Use of Targeted Therapies for Precision Medicine in Oncology. Clinical Chemistry, 2016, 62, 1556-1564.	3.2	10
46	Major milestones in translational oncology. BMC Medicine, 2016, 14, 110.	5.5	15
47	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1333-1340.	2.5	35
48	Genomic profiling for copy number changes in plasma of ovarian cancer patients " a new era for cancer diagnostics?. BMC Medicine, 2016, 14, 186.	5.5	5
49	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. Clinical Chemistry, 2016, 62, 1054-1060.	3.2	87
50	Accuracy of Testosterone Concentrations in Compounded Testosterone Products. Journal of Sexual Medicine, 2015, 12, 1381-1388.	0.6	17
51	Effectiveness of the Risk of Malignancy Index and the Risk of Ovarian Malignancy Algorithm in a Cohort of Women With Ovarian Cancer. International Journal of Gynecological Cancer, 2015, 25, 809-814.	2.5	15
52	False Biomarker Discovery due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125. Clinical Chemistry, 2014, 60, 381-388.	3.2	38
53	Ovarian Cancer Biomarkers. Advances in Clinical Chemistry, 2014, , 25-77.	3.7	20
54	Deciphering the peptidome of urine from ovarian cancer patients and healthy controls. Clinical Proteomics, 2014, 11, 23.	2.1	37

#	ARTICLE	IF	CITATIONS
55	Deciphering the ovarian cancer ascites fluid peptidome. <i>Clinical Proteomics</i> , 2014, 11, 13.	2.1	35
56	Ovarian cancer biomarkers: current state and future implications from high-throughput technologies. <i>Advances in Clinical Chemistry</i> , 2014, 66, 25-77.	3.7	10
57	Fascin-1 is a novel biomarker of aggressiveness in some carcinomas. <i>BMC Medicine</i> , 2013, 11, 53.	5.5	25
58	Quantitative mass spectrometry-based assay development and validation: From small molecules to proteins. <i>Clinical Biochemistry</i> , 2013, 46, 444-455.	1.9	24
59	Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. <i>Translational Proteomics</i> , 2013, 1, 74-86.	1.2	13
60	Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. <i>Clinical Biochemistry</i> , 2013, 46, 1462-1468.	1.9	50
61	Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. <i>Clinical Biochemistry</i> , 2013, 46, 399-410.	1.9	98
62	Targeted Selected Reaction Monitoring Mass Spectrometric Immunoassay for Insulin-like Growth Factor 1. <i>PLoS ONE</i> , 2013, 8, e81125.	2.5	40
63	Validating urinary measurement of beta-2-microglobulin with a Roche reagent kit designed for serum measurements. <i>Clinical Biochemistry</i> , 2012, 45, 1533-1535.	1.9	10
64	CUB and zona pellucida-like domain-containing protein 1 (CUZD1): A novel serological biomarker for ovarian cancer. <i>Clinical Biochemistry</i> , 2012, 45, 1543-1546.	1.9	9
65	From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. <i>Biomarkers in Medicine</i> , 2012, 6, 613-625.	1.4	24
66	Interlaboratory Reproducibility of Selective Reaction Monitoring Assays Using Multiple Upfront Analyte Enrichment Strategies. <i>Journal of Proteome Research</i> , 2012, 11, 3986-3995.	3.7	62
67	Immuno-Mass Spectrometry: Quantification of Low-Abundance Proteins in Biological Fluids. <i>Methods in Molecular Biology</i> , 2011, 728, 207-218.	0.9	9
68	Pediatric reference intervals for 28 chemistries and immunoassays on the Roche cobas® 6000 analyzer—A CALIPER pilot study. <i>Clinical Biochemistry</i> , 2010, 43, 1045-1050.	1.9	44
69	Analytical evaluation of the VITROS® 5600 Integrated System in a pediatric setting and determination of pediatric reference intervals. <i>Clinical Biochemistry</i> , 2010, 43, 1039-1044.	1.9	31
70	Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 371-378.	28.4	140
71	Modification of the Glucose Correction Factor by Peritoneal Dialysis Solution Type in the Peritoneal Equilibration Test. <i>Peritoneal Dialysis International</i> , 2010, 30, 647-650.	2.3	4
72	Nipple Aspirate Fluid Proteome of Healthy Females and Patients with Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 848-855.	3.2	42

#	ARTICLE	IF	CITATIONS
73	Platform for Establishing Interlaboratory Reproducibility of Selected Reaction Monitoring-Based Mass Spectrometry Peptide Assays. <i>Journal of Proteome Research</i> , 2010, 9, 6678-6688.	3.7	78
74	Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 661-669.	3.8	107
75	Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. <i>International Journal of Cancer</i> , 2009, 125, 9-14.	5.1	55
76	Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2746-2758.	3.8	124
77	Tissue culture-based breast cancer biomarker discovery platform. <i>International Journal of Cancer</i> , 2008, 123, 2007-2012.	5.1	66
78	Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 588-599.	4.3	663
79	Product Ion Monitoring Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-Trap. <i>Journal of Proteome Research</i> , 2008, 7, 640-647.	3.7	73
80	Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1997-2011.	3.8	179
81	Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines. <i>Biological Chemistry</i> , 2007, 388, 1113-1119.	2.5	5
82	Proteomic and genomic technologies for biomarker discovery. <i>Clinical Proteomics</i> , 2006, 2, 5-11.	2.1	3
83	Recycling of the Membrane-anchored Chemokine, CX3CL1. <i>Journal of Biological Chemistry</i> , 2005, 280, 19858-19866.	3.4	37
84	Multi-center evaluation of the highly sensitive Abbott ARCHITECT and Alinity thyroglobulin chemiluminescent microparticle immunoassay. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	2.1	1